Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation versus interruption of immunomodulating drugs during infection in IMID patients
NL-OMON54899Active, not recruiting
- Sponsor
- Sint Maartenskliniek
- Start
- Oct 2020
- Countries
- 1
01
Overview
Randomised, open-label trial in autoimmune inflammatory diseases, rheumatoid arthritis (RA), psoriatic arthritis (PsA) and 5 more (2 arms), sponsored by Sint Maartenskliniek. Primary endpoint: Serious infection. Started Oct 2020; status: active, not recruiting.
02
Conditions
autoimmune inflammatory diseasesrheumatoid arthritis (RA)psoriatic arthritis (PsA)axial spondyloarthritis (axSpA)psoriasis
Beyond the preview
Go deeper on NL-OMON54899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54899.